… ProQR Announces Financial Results for the First Quarter of … retinal diseases,” said Daniel A. de Boer, CEO of ProQR. “We expect 2019 to be a transformative year for ProQR … for the same period last year. Research and development (R&D) costs increased to €12.0 million for the quarter ended …
LEIDEN, the Netherlands, April 20, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that Gerard Platenburg, Chief Innovation Officer, will present at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at 12:50pm ET.
LEIDEN, the Netherlands, March 01, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis (CF), Leber's congenital
… ProQR Announces Financial Results for the Second Quarter of … progress towards accomplishing the goals set out in ProQR’s Vision 2023 strategy, which includes starting the … property costs and other allocated costs. The increase in R&D expenses was primarily due to initiation of the clinical …
… ProQR Announces Virtual Presentations at American Academy of … Academy of Ophthalmology (AAO) held November 13-15, 2020. ProQR’s presentations Presentation title: Phase 1b/2 trial … Leber congenital amaurosis 10 (LCA10) Presenter: Stephen R. Russell, MD, Professor and Director of Vitreoretinal …